Received Sep 5, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | J32PB | — |
the administration of the Shingrix adjuvant alone; the administration of the Shingrix adjuvant alone; the patient received vaccine at around age of 40; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of inappropriate preparation of medication in a 40-year-old male patient who received Herpes zoster (Shingrix) (batch number J32PB, expiry date 31-MAR-2027) for prophylaxis. On an unknown date, the patient received Shingrix. On an unknown date, an unknown time after receiving Shingrix, the patient experienced inappropriate preparation of medication (Verbatim: the administration of the Shingrix adjuvant alone), inappropriate dose of vaccine administered (Verbatim: the administration of the Shingrix adjuvant alone) and inappropriate age at vaccine administration (Verbatim: the patient received vaccine at around age of 40). The outcome of the inappropriate preparation of medication, inappropriate dose of vaccine administered and inappropriate age at vaccine administration were not applicable. Additional Information: GSK Receipt Date:28-AUG-2025 Pharmacist reported that wanted to get information regarding the administration of the Shingrix adjuvant alone. The patient was administration of the Shingrix adjuvant alone around at age of 40 years, which led to inappropriate preparation of medication, inappropriate dose of vaccine administered, and inappropriate age at vaccine administration. The vaccine administration facility was the same as primary reporter.